Final results of a placebo-controlled study of filgrastim in small-cell lung cancer: exploration of risk factors for febrile neutropenia.
Publication
, Journal Article
Crawford, J; Glaspy, JA; Stoller, RG; Tomita, DK; Vincent, ME; McGuire, BW; Ozer, H
Published in: Support Cancer Ther
October 1, 2005
BACKGROUND: A phase III study of filgrastim as an adjunct to combination chemotherapy in previously untreated patients with limited- or extensive-stage small-cell lung cancer was conducted. This final analysis explores baseline factors that might predict febrile neutropenia and also reports the results of 463 open-label filgrastim cycles that were delivered after patients' initial episode of the primary endpoint, ie, febrile neutropenia. PATIENTS AND METHODS: A total of 244 patients were randomized to receive placebo or filgrastim in
Duke Scholars
Published In
Support Cancer Ther
DOI
ISSN
1543-2912
Publication Date
October 1, 2005
Volume
3
Issue
1
Start / End Page
36 / 46
Location
United States
Related Subject Headings
- Oncology & Carcinogenesis
Citation
APA
Chicago
ICMJE
MLA
NLM
Crawford, J., Glaspy, J. A., Stoller, R. G., Tomita, D. K., Vincent, M. E., McGuire, B. W., & Ozer, H. (2005). Final results of a placebo-controlled study of filgrastim in small-cell lung cancer: exploration of risk factors for febrile neutropenia. Support Cancer Ther, 3(1), 36–46. https://doi.org/10.3816/SCT.2005.n.023
Crawford, Jeffrey, John A. Glaspy, Ronald G. Stoller, Dianne K. Tomita, Martha E. Vincent, Brian W. McGuire, and Howard Ozer. “Final results of a placebo-controlled study of filgrastim in small-cell lung cancer: exploration of risk factors for febrile neutropenia.” Support Cancer Ther 3, no. 1 (October 1, 2005): 36–46. https://doi.org/10.3816/SCT.2005.n.023.
Crawford J, Glaspy JA, Stoller RG, Tomita DK, Vincent ME, McGuire BW, et al. Final results of a placebo-controlled study of filgrastim in small-cell lung cancer: exploration of risk factors for febrile neutropenia. Support Cancer Ther. 2005 Oct 1;3(1):36–46.
Crawford, Jeffrey, et al. “Final results of a placebo-controlled study of filgrastim in small-cell lung cancer: exploration of risk factors for febrile neutropenia.” Support Cancer Ther, vol. 3, no. 1, Oct. 2005, pp. 36–46. Pubmed, doi:10.3816/SCT.2005.n.023.
Crawford J, Glaspy JA, Stoller RG, Tomita DK, Vincent ME, McGuire BW, Ozer H. Final results of a placebo-controlled study of filgrastim in small-cell lung cancer: exploration of risk factors for febrile neutropenia. Support Cancer Ther. 2005 Oct 1;3(1):36–46.
Published In
Support Cancer Ther
DOI
ISSN
1543-2912
Publication Date
October 1, 2005
Volume
3
Issue
1
Start / End Page
36 / 46
Location
United States
Related Subject Headings
- Oncology & Carcinogenesis